Cover

Current Research in Head and Neck Cancer

Molecular Pathways, Novel Therapeutic Targets, and Prognostic Factors

Editor(s): Bier H. (Düsseldorf) 
Table of Contents
Vol. 62, No. , 2005
Section title: Paper
Bier H (ed): Current Research in Head and Neck Cancer. Adv Otorhinolaryngol. Basel, Karger, 2005, vol 62, pp 121-133
(DOI:10.1159/000082501)
Paper

Chemokine Receptors 6 and 7 Identify a Metastatic Expression Pattern in Squamous Cell Carcinoma of the Head and Neck

Wang J.a · Xi L.b,c · Gooding W.d · Godfrey T.E.b,c · Ferris R.L.a,c
aDepartments of Otolaryngology and Immunology, University of Pittsburgh School of Medicine, Hillman Cancer Center, bDepartment of Surgery, Cancer Institute, University of Pittsburgh School of Medicine, cUniversity of Pittsburgh Cancer Institute and dDepartment of Biostatistics, University of Pittsburgh Cancer Institute, Pittsburgh, Pa., USA

Abstract

Squamous cell carcinoma of the head and neck (HNSCC) metastasizes predictably to locoregional, cervical lymph nodes. Tumor cells can express various receptors that facilitate metastatic spread to lymph nodes and other nonlymphoid organs. Chemokine receptors (CCRs), normally expressed on lymphocytes, control immune and inflammatory cell migration, providing a link between innate and adaptive immunity. CCR expression was evaluated in HNSCC, and we showed a consistent pattern of CCR6 downregulation and upregulation of CCR7 in metastatic cells and tissues. Functional assays indicate that these surface receptors were functional on metastatic tumor cells. CCR6 downregulation is consistent with its decreased expression in cells emigrating from peripheral mucosal sites, while CCR7, important for homing of immune cells to secondary lymphoid organs, was significantly upregulated. Thus, CCR6, CCR7 and their ligands, normally important in controlling immune cell trafficking in response to inflammatory stimuli, may have an important role in determining the metastasis of HNSCC cells in vivo. Our data indicate that inhibition of CCR signaling may provide a targeted molecular therapy to prevent HNSCC metastasis.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.